Progyny (NASDAQ:PGNY) Updates FY 2025 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 1.520-1.620 for the period, compared to the consensus EPS estimate of 1.660. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Progyny also updated its Q1 2025 guidance to 0.440-0.470 EPS.

Progyny Stock Performance

PGNY stock opened at $22.53 on Friday. Progyny has a 52 week low of $13.39 and a 52 week high of $38.98. The company has a market capitalization of $1.92 billion, a PE ratio of 38.85, a price-to-earnings-growth ratio of 2.39 and a beta of 1.34. The company’s 50-day simple moving average is $20.68 and its 200 day simple moving average is $18.69.

Wall Street Analyst Weigh In

PGNY has been the subject of a number of recent analyst reports. Truist Financial reiterated a “hold” rating and set a $19.00 target price (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Bank of America raised their target price on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. upped their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Canaccord Genuity Group raised their target price on Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a report on Friday. Finally, Barclays lowered their price target on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $24.82.

Insiders Place Their Bets

In related news, Chairman David J. Schlanger bought 150,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were purchased at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now owns 228,269 shares of the company’s stock, valued at $3,350,988.92. This represents a 191.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.